Syndax Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Syndax Pharmaceuticals, Inc. (SNDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 7.78 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2022-11-03
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 0.00 shares.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 134.14K shares, a 25.64% decline from fiscal 2018.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2018 was 180.40K shares, a 101.08% increase from fiscal 2017.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 89.72K shares, a 8.86% increase from fiscal 2016.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 82.42K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 7.78K shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 7.78K shares 10-Q · filed 2022-08-08 | |||
| 2019-12-31 | 134.14K shares 10-K · filed 2020-03-05 | |||
| 2018-12-31 | 180.40K shares 10-K · filed 2019-03-07 | |||
| 2017-12-31 | 89.72K shares 10-K · filed 2018-03-08 | |||
| 2016-12-31 | 82.42K shares 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |